INCEPTIONR LLC: CVSA position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of INCEPTIONR LLC on CVSA, newest first. How the timeline and the estimate are built.
INCEPTIONR LLC held 2,171 CVSA shares at 2026-06-30 per its 13F-HR filed 2026-08-11.
the latest 13F is the newest step
- period ended2026-06-3013F 2,171 sharesChange vs previous 13F +2,171 shares
0.07% of the 13F portfolio, value $270,637.
13F-HR 0002085853-26-000978 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-12-3113F 0 sharesChange vs previous 13F -3,557 shares
13F-HR 0002085853-26-000252 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2025-09-3013F 3,557 sharesChange vs previous 13F +761 shares
0.13% of the 13F portfolio, value $549,379.
13F-HR 0002085853-25-000272 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-06-3013F 2,796 sharesChange vs previous 13F +2,796 shares
0.08% of the 13F portfolio, value $355,735.
13F-HR 0001667731-25-001097 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-12-3113F 0 sharesChange vs previous 13F -3,128 shares
13F-HR 0001667731-25-000215 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2024-09-3013F 3,128 sharesChange vs previous 13F not available
0.06% of the 13F portfolio, value $236,101.
13F-HR 0001821561-24-000008 filed by INCEPTIONR LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).